Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Authors:

Abstract
Background: Covalent Bruton tyrosine kinase inhibitors (BTKi) have been an important advancement for the treatment of Waldenström macroglobulinemia (WM), but th